Stock listing

NASDAQ:PASG Passage Bio, Inc. Stock

Home listing (NASDAQ) of Passage Bio, Inc.

Follow Passage Bio, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:PASG

$3.92 USD -0.21 (-5.2%)

Close on Nov 20, 2026

Past year -47.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.51 – $3.94 USDNov 20, 2026
Volume
27,965 sharesNov 20, 2026
Market cap
$12.61M USDAt the close on Nov 20, 2026 · price × 3.22M shares outstanding
52-week range
$3.29 – $20.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$92,068 USDMedian day 15,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Passage Bio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PASG · Home$3.92 USD-0.215 (-5.2%)27,965$3.65$3.94$3.51$4.135Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PASG · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.92-0.215-5.2%$3.65$3.94$3.5127,965
$4.135-0.085-2.0%$4.13$4.24$3.76914,487
$4.22+0.09+2.2%$4.04$4.25$3.9124,651
$4.13-0.12-2.8%$4.12$4.20$3.8416,997
$4.25+0.24+6.0%$4.055$4.25$4.0311,873
$4.01+0.01+0.2%$4.00$4.09$3.4912,365
$4.00+0.22+5.8%$3.86$4.00$3.8027,915
$3.78+0.35+10.2%$3.47$3.78$3.4329,608
$3.43-0.545-13.7%$3.66$3.75$3.434,847
$3.975+0.515+14.9%$3.39$4.00$3.3921,866
$3.46-0.05-1.4%$3.52$3.56$3.3928,146
$3.51+0.11+3.2%$3.459$3.69$3.4525,281
$3.40+0.08+2.4%$3.40$3.48$3.337,687
$3.32-0.13-3.8%$3.45$3.55$3.3211,137
$3.45-0.07-2.0%$3.605$3.605$3.457,173
$3.52+0.19+5.7%$3.44$3.83$3.4416,686
$3.33-0.02-0.6%$3.40$3.565$3.308,034
$3.35-0.009-0.3%$3.31$3.40$3.313,992
$3.359-0.011-0.3%$3.365$3.365$3.3591,602
$3.37-0.14-4.0%$3.63$3.63$3.34521,500
$3.51-0.08-2.2%$3.422$3.86$3.42243,900
$3.59-0.01-0.3%$3.56$3.59$3.472,900
$3.60+0.02+0.6%$3.454$3.68$3.4545,700
$3.58+0.08+2.3%$3.50$3.60$3.4310,900
$3.50-0.10-2.8%$3.61$3.76$3.3716,800
$3.60-0.06-1.6%$3.60$3.92$3.6015,900
$3.66+0.02+0.5%$3.64$3.93$3.627,800
$3.64-0.91-20.0%$4.46$4.46$3.6314,200
$4.55+0.86+23.3%$3.61$4.55$3.6075,200
$3.69-0.09-2.4%$3.83$3.83$3.6112,100
$3.78-0.075-1.9%$3.77$3.83$3.6215,800
$3.855-0.225-5.5%$4.00$4.05$3.76314,100
$4.08-0.01-0.2%$4.13$4.29$4.086,600
$4.09-0.03-0.7%$4.05$4.19$4.0517,900
$4.12-0.081-1.9%$4.29$4.44$4.1117,000
$4.201-0.299-6.6%$4.50$4.734$4.2026,500
$4.50-0.13-2.8%$4.59$4.67$4.3728,900
$4.63-0.045-1.0%$4.61$4.88$4.6124,800
$4.675-0.125-2.6%$4.79$5.072$4.5218,600
$4.800.000.0%$4.78$4.85$4.618,700
$4.80-0.20-4.0%$4.96$5.03$4.7856,600
$5.00+0.05+1.0%$4.86$5.05$4.823,400
$4.95+0.12+2.5%$4.887$4.95$4.7324,100
$4.83+0.08+1.7%$4.76$4.83$4.665117,600
$4.75-0.29-5.8%$4.93$4.935$4.6621,200
$5.04+0.18+3.7%$4.98$5.04$4.753,300
$4.86+0.09+1.9%$4.74$4.915$4.7418,000
$4.77-0.09-1.9%$4.83$4.845$4.709,800
$4.86-0.14-2.8%$4.91$5.03$4.8130,100
$5.00+0.015+0.3%$4.97$5.13$4.907,900
$4.985+0.045+0.9%$4.99$5.215$4.9028,500
$4.94+0.09+1.9%$4.84$5.36$4.74197,200
$4.85+0.20+4.3%$4.63$4.91$4.6314,600
$4.65-0.10-2.1%$4.63$4.875$4.633,800
$4.75+0.14+3.0%$4.60$4.75$4.567,700
$4.61+0.17+3.8%$4.41$4.65$4.413,400
$4.44+0.01+0.2%$4.425$4.445$4.401,300
$4.43-0.09-2.0%$4.52$4.65$4.4016,400
$4.52+0.19+4.4%$4.32$4.60$4.3121,900
$4.33-0.17-3.8%$4.46$4.53$4.3114,000
$4.50-0.33-6.8%$4.79$4.79$4.506,300
$4.83+0.32+7.1%$4.53$4.875$4.5120,720
$4.51+0.07+1.6%$4.37$4.66$4.3039,264
$4.44-0.04-0.9%$4.53$4.725$4.3536,500
$4.48-0.03-0.7%$4.40$4.745$4.4011,300

Splits

1 split · NASDAQ:PASG · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
NASDAQ:PASG
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Passage Bio, Inc. news

Passage Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
4 in the last 12 months · 122 in all · newest Jun 25, 2026 · oldest 2020
Calls
8 calls with a replay · 8 with a transcript · latest Mar 6, 2023
Decks
39 decks · latest Jul 22, 2026

Where Passage Bio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:PASG · Home listing · This pageNASDAQUnited StatesUSD
BOATS:PASGBOATSUnited StatesUSD

Valuation

Price/book 252× against a median of 1.8×: the highest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$7.55M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
252×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.94

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Passage Bio, Inc. · NASDAQ:PASGUS$12.61M−US$7.55Mn/an/an/a252×n/a0.0×1.94
Devonian Health Group, Inc. · TSXV:GSDUS$13.09MUS$12.59Mn/a6.0×n/a2.7×−204.1%0.0×0.12
Bolt Biotherapeutics, Inc. · NASDAQ:BOLTUS$12.80MUS$18.89Mn/a7.5×n/a1.5×n/a2.4×0.52
Avai Bio, Inc. · OTC:AVAIUS$12.79MUS$12.67Mn/an/an/an/an/an/a0.28
Neuphoria Therapeutics Inc. · NASDAQ:NEUPUS$12.72M−US$6.03Mn/an/an/a0.5×n/a0.0×0.61
Seres Therapeutics, Inc. · NASDAQ:MCRBUS$12.64MUS$30.89Mn/a14.5×n/a0.6×n/a1.7×1.21
Allarity Therapeutics, Inc. · NASDAQ:ALLRUS$12.56MUS$21.48Mn/a61.4×n/an/an/an/a1.40
Lobe Sciences Ltd · CSE:LOBEUS$12.52MUS$8.89Mn/an/an/a9.5×n/a0.0×0.31
Biophytis SA · EURONEXT:ALBPSUS$12.47MUS$19.44Mn/an/an/an/an/an/an/a
MIRA Pharmaceuticals, Inc. · NASDAQ:MIRAUS$12.23MUS$5.26Mn/an/an/a1.8×n/a0.0×1.48
Genflow Biosciences PLC · LSE:GENFUS$12.06MUS$11.23Mn/an/an/a48.5×n/a0.0×n/a
Median of the othersUS$12.60MUS$12.63M11.0×1.8×−204.1%0.0×0.56

Forecasts

1 strong buy · 2 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
15.50 USD · Analysts' mean
EPS, year to Dec 2026
-14.08 · 1 analyst

Team and board

Officers

OfficerRole
Athena CountouriotisChief Executive Officer and Chairperson of the board of directors of Avenzo Therapeutics
Derrell D. PorterChief Executive Officer and member of the board of directors of cTRL Therapeutics, Inc.
William ChouPresident and Chief Executive Officer
Sandip KapadiaChief Financial Officer of Harmony Biosciences Holdings, Inc.
Thomas KassbergChief Business Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc.

Board

DirectorRole
Maxine GowenChairwoman

Events

Calls

CallWhenStatus
Passage Bio (NASDAQ:PASG) Q4 2022 Earnings CallMon, Mar 06, 2023 · 8:30 AM ETReplay
Passage Bio (NASDAQ:PASG) Q3 2022 Earnings CallThu, Nov 10, 2022 · 8:30 AM ETReplay
Passage Bio (NASDAQ:PASG) Q2 2022 Earnings CallThu, Aug 04, 2022 · 8:30 AM ETReplay
Passage Bio (NASDAQ:PASG) Q1 2022 Earnings CallMon, May 16, 2022 · 8:30 AM ETReplay
Passage Bio (NASDAQ:PASG) Q4 2021 Earnings CallThu, Mar 03, 2022 · 8:30 AM ETReplay
Passage Bio (NASDAQ:PASG) Q2 2021 Earnings CallThu, Aug 05, 2021 · 8:30 AM ETReplay
Passage Bio (NASDAQ:PASG) Q4 2020 Earnings CallWed, Mar 03, 2021 · 8:30 AM ETReplay
Passage Bio (NASDAQ:PASG) Q3 2020 Earnings CallTue, Nov 10, 2020 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open+10.2%
Q2 2026Aug 10, 2026 · Before open−1.8%
Q1 2026May 19, 2026+1.6%
Q4 2025Mar 3, 2026 · After close+5.5%
Q3 2025Nov 10, 2025 · After close+14.8%
Q2 2025Aug 12, 2025 · Before open−4.9%
Q1 2025May 13, 2025 · Before open−4.2%
Q4 2024Mar 3, 2025 · Before open−7.3%
Q3 2024Nov 13, 2024 · Before open−12.9%
Q2 2024Aug 8, 2024 · Before open−5.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · Before open−10.5%
Q4 2023Mar 4, 2024 · Before open+1.2%
Q3 2023Nov 13, 2023 · Before open0.0%
Q2 2023Aug 7, 2023 · Before open−5.1%
Q1 2023May 11, 2023 · Before open−1.0%
Q4 2022Mar 6, 2023 · Before open0.0%
Q3 2022Nov 10, 2022 · Before open+10.8%
Q2 2022Aug 4, 2022 · Before open+0.9%
Q1 2022May 16, 2022 · Before open−7.7%
Q4 2021Mar 3, 2022 · Before open−11.6%

Open Events

Decks

DeckKindSlidesDate
Merger or Acquisition (July 2026)Merger or acquisition38 slidesJul 22, 2026
Merger or Acquisition (June 2026)Merger or acquisition36 slidesJun 24, 2026
Investor Presentation (April 2026)Investor deck33 slidesApr 20, 2026
Investor Presentation (March 2026)Investor deck34 slidesMar 3, 2026
Investor Presentation (January 2026)Investor deck35 slidesJan 12, 2026
Investor Presentation (November 2025)Investor deck30 slidesNov 10, 2025
Investor Presentation (August 2025)Investor deck31 slidesAug 12, 2025
Investor Presentation (June 2025)Investor deck32 slidesJun 23, 2025
Investor Presentation (May 2025)Investor deck31 slidesMay 13, 2025
AD/PD 2025 International ConferenceConference14 slidesApr 3, 2025
All 39 decks
DeckKindSlidesDate
Investor Presentation (March 2025)Investor deck31 slidesMar 4, 2025
Investor Presentation (November 2024)Investor deck30 slidesNov 13, 2024
ESGCT 2024Conference19 slidesOct 24, 2024
Investor Presentation (September 2024)Investor deck30 slidesSep 16, 2024
Investor Presentation (August 2024)Investor deck29 slidesAug 8, 2024
Investor Presentation (May 2024)Investor deck30 slidesMay 14, 2024
Investor Presentation (March 2024)Investor deck28 slidesMar 4, 2024
Investor Presentation (January 2024)Investor deck28 slidesJanuary 2024
Corporate Update (November 2023)Corporate update29 slidesNov 13, 2023
Technical Presentation (August 2023)Technical23 slidesAug 7, 2023
Corporate Update (May 2023)Corporate update33 slidesMay 11, 2023
Corporate Update (March 2023)Corporate update33 slidesMar 6, 2023
Technical Presentation (February 2023)Technical14 slidesFeb 24, 2023
Investor Presentation (January 2023)Investor deck32 slidesJan 9, 2023
Technical Presentation (December 2022)Technical26 slidesDec 14, 2022
Investor Presentation (November 2022)Investor deck26 slidesNov 10, 2022
Investor Presentation (August 2022)Investor deck34 slidesAug 4, 2022
American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting (May 2022)Conference17 slidesMay 18, 2022
Investor Presentation (May 2022)Investor deck33 slidesMay 16, 2022
Technical Presentation (February 2022)Technical23 slidesFeb 11, 2022
J.P. Morgan 40th Annual Healthcare Conference (January 2022)Conference30 slidesJan 10, 2022
Technical Presentation (December 2021)Technical19 slidesDec 17, 2021
Investor Presentation (November 2021)Investor deck35 slidesNov 4, 2021
Investor Presentation (October 2021)Investor deck35 slidesOct 4, 2021
Investor Presentation (August 2021)Investor deck35 slidesAug 5, 2021
Investor Presentation (May 2021)Investor deck36 slidesMay 5, 2021
Investor Presentation (March 2021)Investor deck34 slidesMar 3, 2021
39th Annual J.P. Morgan Healthcare Conference (January 2021)Conference33 slidesJan 11, 2021
Investor Presentation (September 2020)Investor deck39 slidesSep 9, 2020

Open Decks

IPO

Priced at US$18.00 a share on Feb 27, 2020.

Price
US$18.00 a share
Shares offered
12,000,000 shares of common stock
Offering size
US$216 million
Underwriters' option
Up to 1,800,000 more shares
Listing
PASG on the Nasdaq Global Select Market
Underwriters
J.P. Morgan, Goldman Sachs & Co. LLC, Cowen, Chardan · In the order on the cover
Shares delivered
On or about Mar 3, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceDec 6, 2019
Filed publiclyFeb 3, 2020
Amended twiceNewest Feb 27, 2020
Shares registered with an exchangeFeb 18, 2020
Declared effective by the SECFeb 27, 2020
Final prospectus, with the priceFeb 28, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Feb 28, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue00000000
Cost of revenue728.0K3.08M3.72M3.68M1.54M800.0K134.0K
Gross profit-728.0K-3.08M-3.72M-3.68M-1.54M-800.0K-134.0K
Research and development23.3M40.2M61.4M86.1M117.7M81.8M3.03M9.17M
Selling, general and administrative19.9M25.0M41.6M49.3M60.1M30.1M6.95M928.0K
Operating income-49.3M-70.4M-108.4M-138.4M-185.7M-112.9M-37.2M-13.5M
Depreciation and amortization728.0K3.08M3.72M3.68M1.54M800.0K134.0K134.0K
EBITDA-48.6M-67.3M-104.7M-134.7M-184.2M-112.1M-37.1M-13.3M
Interest expense2.27M343.0K670.0K8.45M696.0K
Income before tax-45.5M-64.8M-102.1M-136.1M-185.4M-112.2M-45.6M-12.8M
Income tax005.39M731.0K6.11M-470.0K8.95M-696.0K
Net income-45.5M-64.8M-102.1M-136.1M-185.4M-112.2M-45.6M-12.8M
Earnings per share, basic-14.35-21.04-1.86-2.50-3.48-2.91-10.77-10.66
Earnings per share, diluted-14.35-21.04-1.86-2.50-3.48-2.91-10.77

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents46.3M37.6M21.7M34.6M129.0M135.0M158.9M24.9M
Short-term investments039.2M92.6M155.0M186.8M169.8M
Receivables4.27M6.20M8.03M
Current assets47.8M78.8M118.0M197.0M325.1M317.2M165.8M33.4M
Property, plant and equipment4.11M9.33M15.3M22.5M23.8M2.79M1.09M28.0K
Total assets62.3M102.4M150.5M243.5M355.1M328.0M178.6M33.5M
Accounts payable1.11M742.0K1.30M4.07M9.45M5.26M629.0K212.0K
Current liabilities23.1M19.4M16.3M18.4M29.5M21.2M3.68M307.0K
Total debt24.0M25.5M26.3M27.1M
Total liabilities43.5M41.2M39.3M42.2M36.4M23.3M4.26M45.6M
Shareholders' equity18.8M61.3M111.3M201.4M318.7M304.7M-56.3M-12.2M
Shares outstanding3.18M3.16M54.9M54.6M54.2M45.6M4.29M1.20M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-31.5M-48.0M-78.3M-118.2M-126.9M-80.5M-39.9M-18.6M
Capital spending0-34.0K-146.0K-5.27M-25.6M-1.65M-1.69M-2.54M
Free cash flow-31.5M-48.0M-78.4M-123.5M-152.5M-82.2M-41.6M-21.1M
Cash from investing40.2M54.9M65.2M25.2M-45.8M-172.1M-1.69M-2.54M
Cash from financing23.0K8.87M135.0K-1.35M166.7M228.8M175.6M46.0M
Share buybacks23.0K97.0K135.0K304.0K887.0K284.0K
Change in cash8.73M15.9M-12.9M-94.4M-6.04M-23.9M134.0M24.9M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 19, 2026Current reportSEC
8-K · Current reportNov 19, 2026Current reportSEC
8-K · Current reportNov 18, 2026Current reportSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 6, 2026Management or board changeSEC
EFFECT · Notice that a registration is effectiveOct 13, 2026Other filingsSEC
424B3 · ProspectusOct 9, 2026Offer documentSEC
S-4/A · Registration statement, amendedOct 8, 2026Offer documentSEC
S-4/A · Registration statement, amendedOct 5, 2026Offer documentSEC
S-4/A · Registration statement, amendedSep 21, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
S-4/A · Registration statement, amendedSep 2, 2026Offer documentSEC
425Sep 2, 2026Other filingsSEC
8-K · Current reportSep 2, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
425Jul 21, 2026Other filingsSEC
S-4 · Registration statementJul 21, 2026Offer documentSEC
SCHEDULE 13D · Big-stake noticeJul 2, 2026Big-stake noticeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJun 25, 2026Big-stake noticeSEC
425Jun 24, 2026Other filingsSEC
425Jun 24, 2026Other filingsSEC
8-K · Current reportJun 24, 2026Material contractSEC
8-K · Current reportMay 27, 2026Current reportSEC
8-K · Current reportMay 26, 2026Meeting outcomeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportApr 28, 2026Current reportSEC
8-K · Current reportApr 20, 2026Current reportSEC
ARS · Annual report to shareholdersApr 7, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 7, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 7, 2026Meeting noticeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
8-K · Current reportMar 10, 2026Current reportSEC
S-8 · Registration statement for employee plansMar 4, 2026Offer documentSEC
10-K · Annual reportMar 3, 2026Annual reportSEC
8-K · Current reportMar 3, 2026ResultsSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026ResultsSEC
144 · Notice of proposed saleJan 9, 2026Other filingsSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
8-K · Current reportSep 18, 2025Management or board changeSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
8-K · Current reportJul 29, 2025Current reportSEC
4 · Change in ownershipJul 24, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 24, 2025Big-stake noticeSEC
144 · Notice of proposed saleJul 21, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 21, 2025Big-stake noticeSEC
144 · Notice of proposed saleJul 15, 2025Other filingsSEC
8-K · Current reportJul 14, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 9, 2025Big-stake noticeSEC
144 · Notice of proposed saleJul 7, 2025Other filingsSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
144 · Notice of proposed saleJun 24, 2025Other filingsSEC
8-K · Current reportJun 23, 2025Current reportSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
8-K · Current reportMay 30, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 25, 2025Big-stake noticeSEC
4 · Change in ownershipApr 24, 2025Insider tradeSEC
4 · Change in ownershipApr 17, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 16, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 16, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 16, 2025Meeting noticeSEC
144 · Notice of proposed saleApr 15, 2025Other filingsSEC
PRE 14A · Preliminary proxy statementApr 4, 2025Meeting noticeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
424B5 · ProspectusMar 5, 2025Offer documentSEC
S-8 · Registration statement for employee plansMar 5, 2025Offer documentSEC
10-K · Annual reportMar 4, 2025Annual reportSEC
8-K · Current reportMar 4, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 12, 2025Insider tradeSEC
8-K · Current reportJan 31, 2025Current reportSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
8-K · Current reportJan 10, 2025ResultsSEC
4 · Change in ownershipJan 8, 2025Insider tradeSEC
144 · Notice of proposed saleJan 6, 2025Other filingsSEC
4 · Change in ownershipDec 31, 2024Insider tradeSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 26, 2024Big-stake noticeSEC
4 · Change in ownershipDec 11, 2024Insider tradeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
144 · Notice of proposed saleDec 4, 2024Other filingsSEC
144 · Notice of proposed saleDec 4, 2024Other filingsSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
8-K · Current reportOct 24, 2024Current reportSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipSep 23, 2024Insider tradeSEC
4 · Change in ownershipSep 18, 2024Insider tradeSEC
144 · Notice of proposed saleSep 16, 2024Other filingsSEC
144 · Notice of proposed saleSep 16, 2024Other filingsSEC
8-K · Current reportSep 16, 2024Current reportSEC
8-K · Current reportSep 10, 2024Management or board changeSEC
8-K · Current reportSep 6, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedAug 9, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedAug 9, 2024Big-stake noticeSEC
3 · Initial statement of ownershipAug 9, 2024Insider tradeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
8-K · Current reportAug 2, 2024Current reportSEC
8-K · Current reportAug 1, 2024ResultsSEC
8-K · Current reportJul 16, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedMay 29, 2024Big-stake noticeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
8-K · Current reportMay 22, 2024Meeting outcomeSEC
424B3 · ProspectusMay 14, 2024Offer documentSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
EFFECT · Notice that a registration is effectiveApr 17, 2024Other filingsSEC
CORRESP · Letter to the SECApr 12, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedApr 12, 2024Big-stake noticeSEC
DEFA14A · Additional proxy materialApr 9, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 9, 2024Meeting noticeSEC
ARS · Annual report to shareholdersApr 9, 2024Annual reportSEC
SC 13G · Big-stake noticeMar 29, 2024Big-stake noticeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
UPLOAD · Letter from the SECMar 7, 2024Other filingsSEC
S-8 · Registration statement for employee plansMar 4, 2024Offer documentSEC
S-3 · Registration statementMar 4, 2024Offer documentSEC
10-K · Annual reportMar 4, 2024Annual reportSEC
8-K · Current reportMar 4, 2024ResultsSEC
8-K · Current reportFeb 29, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2024Insider tradeSEC
4 · Change in ownershipFeb 13, 2024Insider tradeSEC
8-K · Current reportJan 5, 2024Current reportSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
8-K · Current reportDec 29, 2023Current reportSEC
8-K · Current reportDec 20, 2023Current reportSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportNov 13, 2023ResultsSEC
SC 13D/A · Big-stake notice, amendedNov 9, 2023Big-stake noticeSEC
8-K · Current reportSep 1, 2023Current reportSEC
10-Q · Quarterly reportAug 7, 2023Quarterly reportSEC
8-K · Current reportAug 7, 2023ResultsSEC
4 · Change in ownershipAug 1, 2023Insider tradeSEC
4 · Change in ownershipJul 31, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 31, 2023Insider tradeSEC
8-K · Current reportJul 31, 2023Management or board changeSEC
4 · Change in ownershipJul 28, 2023Insider tradeSEC
3 · Initial statement of ownershipJul 28, 2023Insider tradeSEC
8-K · Current reportJul 20, 2023Management or board changeSEC
4 · Change in ownershipJun 29, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJun 29, 2023Big-stake noticeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJun 15, 2023Big-stake noticeSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC
8-K · Current reportMay 26, 2023Meeting outcomeSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC
10-Q · Quarterly reportMay 11, 2023Quarterly reportSEC
8-K · Current reportMay 11, 2023ResultsSEC
4 · Change in ownershipApr 20, 2023Insider tradeSEC
ARS · Annual report to shareholdersApr 14, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 14, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 14, 2023Meeting noticeSEC

This page holds 200 of 447 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Passage Bio, Inc.’s releases · as of Nov 6, 2026

Common shares
3,217,810
Fully diluted
3,217,810

Fully diluted

LineSharesAs of
Common shares3,217,810Nov 6, 2026

Share count over time

CountShares
Nov 6, 20263,217,810

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Lynx1 Capital Management LP674K20.9%US$3.03MSep 30, 2026
Nantahala Capital Management, LLC127K4.0%US$573KSep 30, 2026
Vanguard90,2012.8%US$406KSep 30, 2026
Yiheng Capital Management, L.P.86,0972.7%US$387KSep 30, 2026
Verdad Advisers, LP57,9971.8%US$261KSep 30, 2026
Balyasny Asset Management L.P.49,5141.5%US$223KSep 30, 2026
Renaissance Technologies46,8921.5%US$211KSep 30, 2026
Erste Asset Management GmbH40,6651.3%US$188KSep 30, 2026
Geode Capital37,0261.2%US$167KSep 30, 2026
BlackRock27,9100.87%US$126KSep 30, 2026
All 27 holders
HolderSharesOf the companyValueAs of
Acadian Asset Management LLC22,4960.70%US$100KSep 30, 2026
Jane Street17,9930.56%US$80,969Sep 30, 2026
Deltec Asset Management LLC15,0000.47%US$67,500Sep 30, 2026
Hrt Financial LP14,8660.46%US$66,000Sep 30, 2026
Fiduciary Trust Co10,7500.33%US$48,375Sep 30, 2026
Gts Securities LLC10,0000.31%US$45,000Sep 30, 2026
UBS4170.01%US$1,877Sep 30, 2026
Morgan Stanley3620.01%US$1,630Sep 30, 2026
Tower Research Capital LLC (TRC)3590.01%US$1,616Sep 30, 2026
Barclays214<0.01%US$963Sep 30, 2026
SBI Securities Co., Ltd.181<0.01%US$815Sep 30, 2026
Wells Fargo115<0.01%US$518Sep 30, 2026
JPMorgan15<0.01%US$69Sep 30, 2026
Osaic Holdings, Inc.15<0.01%US$67Sep 30, 2026
LRI Investments, LLC12<0.01%US$54Sep 30, 2026
BNP Paribas12<0.01%US$54Sep 30, 2026
Harbour Investments, Inc.3<0.01%US$14Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund78,7642.4%US$384KJun 30, 2026
Vanguard Extended Market Index Fund35,2001.1%US$172KJun 30, 2026
Fidelity Extended Market Index Fund18,5350.58%US$107KMay 31, 2026
Fidelity Total Market Index Fund6,4270.20%US$37,084May 31, 2026
Fidelity Series Total Market Index Fund4,7830.15%US$27,598May 31, 2026
LVIP Dimensional U.S. Core Equity 2 Fund2,0220.06%US$9,867Jun 30, 2026
Fidelity Nasdaq Composite Index Fund1,8970.06%US$10,946May 31, 2026
Dimensional U.S. Core Equity 2 ETF7920.02%US$3,540Jul 31, 2026
Diversified Equity Alpha Master Portfolio5040.02%US$2,460Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Nichols Weston
10% owner
Buy50,055USD 4.12US$206KJun 25, 2026

Big stakes

StakeStakeSharesDateFiling
Baselake Partners, LP7.30%235KJun 18, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jill Quigley
Other companies: Chemomab Therapeutics Ltd. (Board Director · Since at least Jun 16, 2022); Terns Pharmaceuticals, Inc. (Director · Since at least Feb 4, 2021)
Chief Operating Officer · Feb 27, 2020 – Dec 8, 2021 · Past
Saqib Islam
Other companies: SpringWorks Therapeutics Inc (Chief Executive Officer, Director · Since at least Jan 7, 2021); ARS Pharmaceuticals, Inc. (Director · Since at least Dec 3, 2020)
Director · Since at least May 27, 2021
Derrell D. Porter
Other companies: Acumen Pharmaceuticals, Inc. (CEO: cTRL Therapeutics, Inc. · Since at least Jan 4, 2023)
Chief Executive Officer and member of the board of directors of cTRL Therapeutics, Inc. · Since at least May 27, 2021
Mark S Forman
Other companies: Ventyx Biosciences Inc (Chief Medical Officer · Since at least Aug 12, 2024)
CHIEF MEDICAL OFFICER · Mar 30, 2022 – Mar 15, 2024 · Past
Monika Maria Toernsen
Other companies: Immunic, Inc. (Director · Since at least Jul 5, 2022)
Chief Commercial Officer · Jul 19, 2021 – Sep 15, 2022 · Past
Thomas Kassberg
Other companies: Ultragenyx Pharmaceutical Inc. (CBO & EVP · Oct 23, 2023 – Mar 1, 2025 · Past)
Chief Business Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc. · Since at least Sep 10, 2024
Athena CountouriotisChief Executive Officer and Chairperson of the board of directors of Avenzo Therapeutics · Since at least Nov 5, 2026
Bruce A GoldsmithCEO and President, Director · Feb 27, 2020 – May 27, 2022 · Past
Dolan SondhiDirector · Since at least Jul 27, 2023
Edgar B CaleGC & CORPORATE SECRETARY · Feb 27, 2020 – Mar 15, 2025 · Past
All 14 people
PersonSeat
Eliseo Oreste SalinasChief Res. & Develop Officer · Mar 22, 2021 – Feb 10, 2022 · Past
Maxine GowenChairwoman · Since at least Nov 5, 2026
Sandip KapadiaChief Financial Officer of Harmony Biosciences Holdings, Inc. · Since at least Nov 5, 2026
William ChouPresident and Chief Executive Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Passage Bio, Inc.